AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy ; volume:8 ; number:1 ; day:1 ; month:8 ; year:2015 ; pages:1-4 ; date:12.2015
Journal of hematology & oncology ; 8, Heft 1 (1.8.2015), 1-4, 12.2015
- Creator
-
Wu, Jingjing
Fu, Jiaping
Zhang, Mingzhi
Liu, Delong
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-015-0188-3
- URN
-
urn:nbn:de:101:1-2021081621591530771719
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wu, Jingjing
- Fu, Jiaping
- Zhang, Mingzhi
- Liu, Delong
- SpringerLink (Online service)
Other Objects (12)
Use of TCR antibody fusion proteins as bispecific agents for NK and T cell-mediated immunotherapy
Mitochondrial apoptosis: facilitator of NK cell-mediated immunotherapy
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Biomaterials Facilitating Dendritic Cell‐Mediated Cancer Immunotherapy
Elastic Nanovaccine Enhances Dendritic Cell‐Mediated Tumor Immunotherapy
TLR9 agonism differentially impacts human NK cell-mediated direct killing and antibody-dependent cell-mediated cytotoxicity
Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
STAT1 signaling shields T cells from NK cell-mediated cytotoxicity
Bispecific antibodies come to the aid of cancer immunotherapy
KIR-HLA footprints and NK cell-mediated recognition of HIV-1
Endogenous/Exogenous Nanovaccines Synergistically Enhance Dendritic Cell‐Mediated Tumor Immunotherapy
Use of TCR antibody fusion proteins as bispecific agents for NK and T cell-mediated immunotherapy
Mitochondrial apoptosis: facilitator of NK cell-mediated immunotherapy
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Biomaterials Facilitating Dendritic Cell‐Mediated Cancer Immunotherapy
Elastic Nanovaccine Enhances Dendritic Cell‐Mediated Tumor Immunotherapy
TLR9 agonism differentially impacts human NK cell-mediated direct killing and antibody-dependent cell-mediated cytotoxicity
Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
STAT1 signaling shields T cells from NK cell-mediated cytotoxicity
Bispecific antibodies come to the aid of cancer immunotherapy
KIR-HLA footprints and NK cell-mediated recognition of HIV-1
Endogenous/Exogenous Nanovaccines Synergistically Enhance Dendritic Cell‐Mediated Tumor Immunotherapy
Use of TCR antibody fusion proteins as bispecific agents for NK and T cell-mediated immunotherapy
Mitochondrial apoptosis: facilitator of NK cell-mediated immunotherapy
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Biomaterials Facilitating Dendritic Cell‐Mediated Cancer Immunotherapy
Elastic Nanovaccine Enhances Dendritic Cell‐Mediated Tumor Immunotherapy
TLR9 agonism differentially impacts human NK cell-mediated direct killing and antibody-dependent cell-mediated cytotoxicity
Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells
NKG2D-bispecific enhances NK and CD8+ T cell antitumor immunity
STAT1 signaling shields T cells from NK cell-mediated cytotoxicity
Bispecific antibodies come to the aid of cancer immunotherapy
KIR-HLA footprints and NK cell-mediated recognition of HIV-1